Skip to main content

Advertisement

Advertisement

World

Moderna says COVID-19 vaccine protection wanes, makes case for booster

Moderna says COVID-19 vaccine protection wanes, makes case for booster

FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Moderna logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic

CHICAGO: New data from Moderna's large COVID-19 vaccine trial shows that the protection it offers wanes over time, supporting the case for booster doses, the company said in a news release on Wednesday (Sep 15).

"This is only one estimate, but we do believe this means as you look toward the fall and winter, at minimum we expect the estimated impact of waning immunity would be 600,000 additional cases of COVID-19," Moderna President Stephen Hoge said on a conference call with investors.

Hoge did not project how many of the cases would be severe, but said some would require hospitalisation.

The data stands in stark contrast with data from several recent studies that suggested Moderna's vaccine protection lasts longer than a similar shot from Pfizer and German partner BioNTech. Experts said the difference is likely due to Moderna's higher dose of messenger RNA (mRNA) and the slightly longer interval between the first and second shots.

Both vaccines proved to be exceedingly effective at preventing illness in their large Phase III studies.

Wednesday's analysis, however, showed higher rates of infection among people vaccinated roughly 13 months ago compared with those vaccinated roughly eight months ago.

The study period was from July to August, when Delta was the predominant strain. It has yet to undergo peer review.

Moderna on Sep 1 submitted its application to the US Food and Drug Administration (FDA) seeking authorisation for a booster shot. Briefing documents from the FDA's analysis of Pfizer's booster application, released earlier on Wednesday, suggest that a key issue the agency will consider is whether vaccine protection is waning.

Hoge said data from its booster studies shows the vaccine could increase neutralising antibodies to levels even higher than were seen after the second dose.

"We believe this will reduce COVID-19 cases," he said. "We also believe that a third dose of mRNA-1273 has a chance of significantly extending immunity throughout much of next year as we attempt to end the pandemic."

In its analysis, Moderna compared the vaccine's performance in more than 14,000 volunteers vaccinated between July and October of 2020 with around 11,000 volunteers originally in the placebo group who were offered the shot between December 2020 and March 2021 following its US emergency-use authorisation.

In July and August this year, researchers identified 88 COVID-19 cases among those who got the two shots in the recent period, compared with 162 cases among those vaccinated earlier. Overall, only 19 cases were considered severe, a key benchmark in assessing waning protection.

Moderna said there was a trend toward a lower rate of severe cases among the more recently vaccinated, although the finding was not statistically significant.

Data from a separate study presented on Wednesday conducted with Kaiser Permanente Southern California health system, meanwhile, shows that Moderna's vaccine continued to perform well against the Delta variant.

Researchers compared data on more than 352,000 people who got two doses of the Moderna vaccine with the same number of unvaccinated individuals and found the Moderna vaccine was 87 per cent effective at preventing a COVID-19 diagnosis, and 96 per cent effective at preventing hospitalisation.

Hoge said the vaccine's initial performance is strong, but argued that protection should not be allowed to wane.

"The first six months are great, but you can't count on that being stable out to a year and beyond," he said.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

 

Source: Reuters/jt

Advertisement

Also worth reading

Advertisement